I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

EURETINA 2025

-
06:00 AM
Duration 10mins Palais des Congrès
Quantitative Ultra-Widefield Fluorescein Angiography for the Assessment of Novel Biomarkers of Vascular Stability With Faricimab▼: A YOSEMITE/RHINE Post Hoc Analysis
Justis Ehlers, Matar K, Indurkar A, Della Vecchia L, Amine R, Mamone J, Tang A, Gibson K, Dagincourt N, Mar F, Amador M, Warter A, Sim D
Duration 10mins Palais des Congrès
RHONE-X Extension Study: Clinical Improvements in Eyes With DME Switched From Aflibercept to Faricimab▼
Ian Pearce, Starr M, Sheth V, Khanani A, Jones C, Gibson K, Lai T, Schlottmann P, Sim D
Duration 10mins Palais des Congrès
Treatment Response and Safety of Faricimab▼ in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US
Steve Huddleston, Emanuelli A, Amador M, Brown J, Coney J, Cunningham M, Gonzalez L, Scott A, Milunovich S, Yang M, Lu X-Y
Duration 10mins Palais des Congrès
Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Patients With DME From a Global, Prospective Observational Study: The VOYAGER Study
Koh A, Schmitz-Valckenberg S, Bailey C, Chaudhary V, Chi G, Downey A, Schweitzer J, Finger R, Parravano M, Sheth V, Kardatzke D, Robyn Guymer
Duration 10mins Palais des Congrès
Effectiveness and Safety of Faricimab▼ in Eyes With DME Beyond Year 1: Results From the UK FARWIDE-DME Study
Kiire C, Ian Pearce, Peto T, Sivaprasad S, Reynolds R, Bailey C, Downey L, Chi G, James N, Downey A, Dodds M, Dayal P
Duration 10mins Palais des Congrès
Faricimab▼ for Angioid Streaks in Japan: Week 12 Results From NIHONBASHI
Tomohiro Iida, Akitaka Tsujikawa, Hideki Koizumi, Ryusaburo Mori, Haruka Ochi, Junko Sato, Keisuke Iwasaki
Duration 10mins Palais des Congrès
The APAC Vision Health Survey Report: An urgent challenge and a critical conjunction
Wei Kiong Ngo, Andrew Chang, Marten Brelen, Kenneth Fong, Harvey Uy, Gavin Tan, Seung-Young Yu, Chi Chun Lai, Paisan Ruammviboonsuk, Shilpika Das, Rancy Khosla
Duration 10mins Palais des Congrès
Assessing a 36-Week Refill-Exchange Regimen for the PDS in Patients With Up To 2 Years Diagnosis of nAMD: Phase 3b Sightspire Trial
Holz F, Khanani A, Paudel N, Zinkernagel M, Dakouras A, Foxton R, Dena Howard, Liu B, Scheidl S, Tian K
Duration 10mins Palais des Congrès
The Impact of Improvements to Surgical Procedure on the Incidence of Endophthalmitis and Associated Outcomes of Patients in the PDS Clinical Development Programme
Cheung G, Chang M, Chaudhry N, Campochiaro P, Chang M, Pieramici P, Regillo C, Bobbala A, Gune S, Jaycock P, Kardatzke D, Prager A, Singh N
Duration 10mins Palais des Congrès
The Phase 1/2 Burgundy Study of Zifibancimig Administered via Intravitreal Injection and the PDP in Patients With nAMD: Rationale and Study Design
Graff J, Wolfe J, Haug S, Dhoot D, Kim J, Kwong M, Callaway N, Orduna J, Steiert B, Wollenhaupt M, Wentzel C
08:51 AM
09:09 AM
Duration 6mins Palais des Congrès
Impact of Continuous Ranibizumab Delivery via the PDS on Nonperfusion and Vascular Leakage in Eyes With Diabetic Retinopathy or Diabetic Macular Edema
Couturier A, Gill M, Balaratnasingam C, Emanuelli A, Suner I, Dakouras A, Latkany P, Plenty A, Gune S
09:15 AM
Duration 6mins Palais des Congrès
Impact of Continuous vs Treatment in Bilateral DME: Efficacy and Safety Outcomes in PDS-Treated Study Eyes vs Anti-VEGF Injection-Treated Fellow Eyes in the Pagoda Trial
Udaondo P, Eichenbaum D, Graff J, Hsieh YT, Hsu J, Wirthlin R, Blotner S, Gune S, Heinrich D, Jones M, Santhanankrishnan A, Schimpl A
09:21 AM
09:33 AM
Duration 6mins Palais des Congrès
Retinal Fluid and Thickness Fluctuations in Patients With Diabetic Macular Edema: Impact of Continuous Delivery of Ranibizumab With the PDS From the Pagoda Trial Through Year 2
Eter N, Awh C, Hatz K, Marcus D, Tan G, Blotner S, Eghoej M, Gordon A, Heinrich D, Menezes A
09:39 AM
01:42 PM
09:00 AM
12:45 PM
Duration 6mins Palais des Congrès
Faricimab▼ for Polypoidal Choroidal Vasculopathy: 1-Year Results From the Phase 3b/4 SALWEEN Trial
Tim Lai, Chen SJ, Cheung G, Iida T, Koh A, Lee J, Lee WK, Li X, Ruamviboonsuk P, Sun X, Yanagi Y, Bai R, Duc AN, Margaron P
12:51 PM
Duration 6mins Palais des Congrès
Effectiveness and Safety of Faricimab▼ in nAMD Eyes Beyond Year 1: Results From the UK FARWIDE-nAMD Study
Gabriella De Salvo, Varma D, Talks J, Patel P, De Silva S, Gale R, Mckibbin M, Chi G, James N, Downey A, Dodds M, Dayal P
01:15 PM
01:27 PM
Duration 6mins Palais des Congrès
Real-World Treatment Patterns and Ocular Morbidity in Patients with Uveitic Macular Oedema (UME) Secondary to Non-Infectious Uveitis (NIU) in the United States (US)
Rachael Harlow, Quan Dong Nguyen, Jia-Horung Hung, Lu Chen, Parul Dayal, Navdeep Pal, Ivaylo Stoilov, Marina Mesquida, Zdenka Haskova, Laura Steeples
01:39 PM
Duration 6mins Palais des Congrès
Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Patients With nAMD From a Global, Prospective Observational Study: The VOYAGER Study
Robyn Guymer, Schmitz-Valckenberg S, Bailey C, Chaudhary V, Chi G, Downey A, Schweitzer J, Finger R, Koh A, Parravano M, Sheth V, Kardatzke D
02:15 PM
Duration 6mins Palais des Congrès
Four-Year Outcomes of Faricimab▼ in nAMD: Safety and Efficacy Results From the AVONELLE-X Long-Term Extension Trial
Veeral Sheth, Shriji Patel, Arshad M. Khanani, Marta S. Figueroa, Robyn Guymer, Timothy Y. Y. Lai, Andrew Lotery, Patricio Schlottmann, Charles C. Wykoff, Ruobing Bai, Philippe Margaron, Yannan Tang, Aachal Kotecha
12:39 PM
Duration 6mins Palais des Congrès
Pigment Epithelial Detachment Thickness Fluctuations in the Phase 3 Archway Trial of the PDS in Neovascular Age-Related Macular Degeneration
Kodjikian L, Brodie F, Graff J, Lai T, Malik D, Ruiz-Medrano J, Priglinger S, Blotner, Gordon A, Holekamp N, Prager, A Heinrich D
12:45 PM
12:51 PM
Duration 6mins Palais des Congrès
Five-Year Efficacy and Safety Outcomes in Patients With Neovascular Age-Related Macular Degeneration Enrolled in the Archway Study and Treated With the PDS
Graff J, Kitchens J, Andrea-Thanei G, Blotner S, Gune S, Rabena M, Singh N
01:54 PM
Duration 6mins Palais des Congrès
Association of Early Macular Leakage Resolution With Extended Dosing Intervals in Patients With RVO: A BALATON/COMINO Post Hoc Analysis
Christiana Dinah, Danzig C, Bhatt H, Dagincourt N, Pereira LP, Schweitzer J, Thommen J
Coming soon